Antineutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis is a common cause of acute kidney injury in the elderly. This patient group is particularly susceptible to disease-related morbidity and mortality, and to adverse effects of induction immunosuppression. A new study adds to the debate on the most appropriate way to treat this vulnerable group of patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Moutzouris, D. A. et al. Renal biopsy in the very elderly. Clin. J. Am. Soc. Nephrol. 4, 1073–1082 (2009).
Harper, L. & Savage, C. O. ANCA-associated renal vasculitis at the end of the twentieth century—a disease of older patients. Rheumatology (Oxford) 44, 495–501 (2005).
Chen, M., Yu, F., Zhang, Y. & Zhao, M. H. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore) 87, 203–209 (2008).
Little, M. A. et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann. Rheum. Dis. 69, 1036–1043 (2010).
Flossman, O. et al. Long-term patient survival in ANCA-associated vasculitis. Ann. Rheum. Dis. 70, 488–494 (2011).
Mukhtyar, C. & Luqmani, R. Disease-specific quality indicators, guidelines, and outcome measures in vasculitis. Clin. Exp. Rheumatol. 25 (Suppl. 47), 120–129 (2007).
Bomback, A. S. et al ANCA-associated glomerulonephritis in the very elderly. Kidney Int. doi:10.1038/ki.2010.489.
de Groot, K. et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med. 150, 670–680 (2009).
Stone, J. H. et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N. Engl. J. Med. 363, 221–232 (2010).
Jones, R. B. et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N. Engl. J. Med. 363, 211–220 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tarzi, R., Pusey, C. Risks and rewards of treating elderly patients with vasculitis. Nat Rev Nephrol 7, 253–255 (2011). https://doi.org/10.1038/nrneph.2011.30
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2011.30
This article is cited by
-
Aging in Primary Systemic Vasculitis: Implications for Diagnosis, Clinical Manifestations, and Management
Drugs & Aging (2019)
-
Issues in trial design for ANCA-associated and large-vessel vasculitis
Nature Reviews Rheumatology (2014)
